Clinical Trial Detail

NCT ID NCT03719105
Title Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York Medical College
Indications

mature T-cell and NK-cell lymphoma

angioimmunoblastic T-cell lymphoma

aggressive NK-cell leukemia

peripheral T-cell lymphoma

Therapies

Pembrolizumab

Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone

Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate

Age Groups: adult child

No variant requirements are available.